Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
SciSparc Ltd. ( (SPRC) ) just unveiled an announcement.
On January 15, 2025, SciSparc Ltd. announced it received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. This extension allows the company time until July 14, 2025, to meet the bid price rule, with plans to potentially conduct a reverse share split if necessary. The Nasdaq decision does not immediately affect SciSparc’s stock listing or trading on the Nasdaq Capital Market, maintaining its current status.
More about SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company that develops therapies for disorders and rare diseases of the central nervous system. The company focuses on cannabinoid pharmaceuticals and is currently engaged in drug development programs for conditions such as Tourette Syndrome, Alzheimer’s disease, autism, and status epilepticus. Additionally, it owns a subsidiary specializing in hemp seeds’ oil-based products sold through Amazon.com.
YTD Price Performance: 94.10%
Average Trading Volume: 8,510,414
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $7.84M
See more insights into SPRC stock on TipRanks’ Stock Analysis page.
